66. IgA腎症 IgA nephropathy Clinical trials / Disease details
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2100004723 | 2021-04-10 | 2021-04-10 | A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy | A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy | IgA nephropathy | Kunxian capsule group:Kunxian capsule and Hydroxychloroquine placebo;Hydroxychloroquine group:Hydroxychloroquine and Kunxian capsule placebo;Placebo group:Kunxian capsule and Hydroxychloroquine placebo; | Peking University First Hospital | NULL | Recruiting | 18 | Both | Kunxian capsule group:65;Hydroxychloroquine group:65;Placebo group:65; | China | ||
| 2 | ChiCTR2100045306 | 2021-04-10 | 2021-04-10 | A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy | A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy | IgA nephropathy | Hydroxychloroquine group:Hydroxychloroquine and Kunxian capsule placebo;Kunxian capsule group:Kunxian capsule and Hydroxychloroquine placebo;Placebo group:Kunxian capsule and Hydroxychloroquine placebo; | Peking University First Hospital | NULL | Recruiting | 18 | Both | Hydroxychloroquine group:65;Kunxian capsule group:65;Placebo group:65; | China | ||
| 3 | NCT02187900 (ClinicalTrials.gov) | June 2014 | 22/6/2014 | Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. | Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f | IgA Nephropathy | Drug: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Drug: Mycophenolate mofetil (MMF) | Second Xiangya Hospital of Central South University | NULL | Recruiting | 16 Years | 65 Years | Both | 300 | Phase 3 | China |
| 4 | ChiCTR-TRC-12002228 | 2012-06-15 | 2012-02-03 | The Clinical Study on the Dispelling Wind-dampness of IgA Nephropathy | The Clinical Study on the Dispelling Wind-dampness of the chronic nephropathy: The Clinical Study on the Dispelling Wind-dampness of IgA Nephropathy(Multi-center, double-blind, randomized, controlled clinical trial program) | IgA Nephropathy | Treatment group:IgA nephropathy side (granules)+TWP tablet;Control group:Chinese medicine simulation granules + The Tripterygium simulation piece; | Hangzhou Hospital of Traditional Chinese Medicine | NULL | Completed | 16 | 65 | Both | Treatment group:114;Control group:114; | China | |
| 5 | ChiCTR-OPN-16010028 | 2011-01-01 | 2016-11-23 | Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria | Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria | IgA nephropathy | Prednisone (PRE) group:1mg/kg prednisone once daily;conventional-dose TW (CTW) group:60 mg TW daily;double-dose TW (DTW) group:?????120mg; | Yancheng Third People's Hospital | NULL | Completed | 21 | 54 | Both | Prednisone (PRE) group:10;conventional-dose TW (CTW) group:10;double-dose TW (DTW) group:10; | NULL | |
| 6 | NCT00885547 (ClinicalTrials.gov) | March 2009 | 20/4/2009 | Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis | Prospective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis. | IgA Nephropathy | Drug: tripterygium wilfordii (TW) | Nanjing University School of Medicine | NULL | Terminated | 18 Years | 60 Years | Both | 90 | N/A | China |